Core Points - PreveCeutical Medical Inc. has announced the effective date of the reclassification and the plan of arrangement with BioGene Therapeutics Inc. to occur on November 25, 2025 [1][4]. Group 1: Arrangement Details - Under the Arrangement Agreement, 12,000,000 common shares of BioGene Therapeutics Inc. will be distributed to PreveCeutical shareholders [2][5]. - The arrangement will involve renaming PreveCeutical's current shares to 'Class A Common Shares without par value' and creating a new class of shares with identical terms and rights [2][5]. Group 2: Share Exchange - On the effective date, each PreveCeutical Current Share will be exchanged for one New PreveCeutical Share and 0.02 BioGene Spinout Shares, rounded down to the nearest whole share [3][6]. Group 3: Security Information - The old security name will remain as PreveCeutical Medical Inc. - Common Shares, with the anticipated payment date set for November 25, 2025, and the delist date on November 24, 2025 [7].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Firefly Aerospace securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to seek recovery of investor losses [2]. - The investigation follows a report from The Wall Street Journal indicating that Firefly Aerospace posted a wider loss and lower revenue in its latest quarter, leading to a significant stock price drop of 15.3% on September 23, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Company Overview - AtlasClear Holdings, Inc. is a technology-driven provider focused on modernizing trading, clearing, settlement, and banking for emerging financial institutions and fintechs [5] - The company operates through its subsidiary Wilson-Davis & Co., Inc., a full-service correspondent broker-dealer, and is in the process of acquiring Commercial Bancorp of Wyoming [5] Upcoming Presentation - AtlasClear's Executive Chairman John Schaible and President Craig Ridenhour will present at NobleCon21 on December 2-3, 2025 [1][2] - The presentation will outline the company's integrated clearing, custody, banking, and digital asset strategy, emphasizing its growth and market opportunities [2] Financial Position - AtlasClear is entering a new growth phase with positive equity and a strengthened capital position [2] - The company is expanding its correspondent clearing pipeline, indicating a robust outlook for future operations [2] Event Details - The presentation is scheduled for December 3, 2025, at 12:30 PM Eastern Time [3] - Leadership will be available for one-on-one meetings with investors during the event [3] Webcast Information - A high-definition video webcast of the presentation will be available the following day on the company's website and other platforms, archived for 90 days [4]

Core Insights - DealMaker Sports and Xtreme One Entertainment have formed a strategic collaboration to enhance fan ownership in the sports industry, particularly in the fight game [1][2] - This partnership signifies a cultural and financial shift towards community ownership in global sports, leveraging the $2.4 trillion retail capital markets [2][3] - The collaboration aims to transform the Xtreme Fighting Championships (XFC) into a league where fans not only watch but also own a stake, aligning passion with capital [4][5] Company Overview - DealMaker Sports is focused on pioneering fan-led ownership in sports, providing fans with a real stake in the teams and leagues they support [3][4] - Xtreme One Entertainment, the parent company of XFC, is dedicated to live sports and event marketing, with a strong media presence reaching over 65 million households globally [3][8] - DealMaker has successfully raised over $2 billion in capital, utilizing an AI-driven platform to facilitate capital raising directly from retail investors [5] Market Positioning - The collaboration is expected to set a new standard for engagement in sports, emphasizing transparency, access, and shared value among fans [2][3] - XFC has established media rights and scalable infrastructure, positioning it for accelerated commercial expansion through partnerships with major media platforms [3][8] - The initiative is part of a broader trend in the sports industry towards fan-driven capital, which is reshaping the economics of teams and leagues worldwide [2][4]

Core Points - The Toronto Stock Exchange (TSX) has launched the first Canada Climate Week Xchange (CCWX) to address climate-related challenges and opportunities in Canada from 2025 to 2030 [1][2] - CCWX 2025 is taking place from November 24-30 and features nearly 100 events in its inaugural year [2] - The initiative aims to foster collaboration among various organizations, including Canadian listed companies, to drive effective climate action [3] Company Involvement - TSX is collaborating with founding members such as Canada Climate Law Initiative, CPA Canada, First Nations Financial Management Board, GLOBE, and Responsible Investment Association to ensure diverse representation in climate action efforts [2][3] - Eliza Riego, Managing Director of Product Innovation and ESG Strategy at TSX, emphasized the importance of sustained collaboration for successful climate action [3] Industry Impact - The CCWX initiative is expected to enhance cross-collaboration on climate issues, potentially leading to new investment opportunities and strategies within the Canadian market [2][3] - A comprehensive listing of events is available at www.ccwx.ca, indicating a structured approach to engaging various stakeholders in climate discussions [3]

Core Points - Green Impact Partners Inc. (GIP) plans to conduct a non-brokered private placement of common shares priced at $4.00 per share, aiming for gross proceeds between $3,000,000 and $5,000,000 [1][2] - The proceeds will be utilized for general working capital and to facilitate financial closure on the Future Energy Park project, with the offering expected to close in November 2025, pending regulatory approvals [2][4] - The offering is available to purchasers in all Canadian provinces except Quebec and certain foreign jurisdictions, under the Listed Issuer Financing Exemption [4] Company Overview - Green Impact Partners Inc. focuses on sustainable energy solutions by converting waste into energy, particularly through renewable natural gas (RNG) and bioenergy projects [6] - The company is involved in the entire project lifecycle, from development to operation, and also manages water and solids treatment and recycling facilities in Canada and the U.S. [6][7]

Core Insights - CEO.CA is a leading investor social network focused on junior resource and venture stocks, providing exclusive updates and insights to CEOs of junior mining explorers [1][2] - Founded in 2012, CEO.CA has become one of the most popular free financial websites and apps in Canada, attracting millions of global investors to discuss stocks, commodities, and emerging companies [2][6] - The platform serves as a media partner at investor events worldwide, covering companies that are shaping the future of mining and engaging with industry leaders to understand their strategies [3] Company Overview - CEO.CA is a wholly owned subsidiary of EarthLabs, Inc., and has established itself as a prominent community for investors and traders in junior resource and venture stocks [6][7] - The platform has facilitated connections among millions of investors from over 164 countries, promoting discussions about portfolio holdings and investment opportunities [6] Engagement and Content - CEO.CA features a series called 'Inside the Boardroom,' where executives from companies like Graphene Manufacturing Group Ltd. share insights and engage with the investor community [4] - The platform encourages companies to showcase themselves through various opportunities, enhancing visibility and engagement with potential investors [5]

Core Insights - Safe Supply Streaming Co Ltd. has entered into an Exclusive Territory License and Commercial Agreement with Healthy Sprays LLC, granting Safe Supply exclusive Canadian rights to distribute Healthy Sprays' GLP-1 solutions [1][4][5] Company Overview - Safe Supply is focused on advancing innovation in healthcare and wellness through strategic partnerships and acquisitions, aiming to improve health outcomes and accessibility [13] - Healthy Sprays is a U.S.-based leader in non-injectable metabolic health solutions, utilizing proprietary sublingual spray technology for its product line [2][12] Licensing Agreement Details - The Licensing Agreement will commence in January 2026 for an initial five-year period, with provisions for extension [4] - Safe Supply will pay a one-time, non-refundable license fee of USD $250,000, along with royalties on Canadian gross sales and fixed-cost purchases of product packaging and delivery technology from Healthy Sprays [6][8] Market Positioning - The partnership is expected to enhance consumer accessibility to modern healthcare solutions in Canada, particularly for those seeking alternatives to injectable therapies [3][4] - With the exclusivity granted, Safe Supply is positioned to lead the market as GLP-1 solutions gain mainstream adoption in Canada [5] Financial Aspects - Safe Supply is proposing a non-brokered private placement of units at C$0.05 per unit, aiming for gross proceeds of up to C$500,000 to fund the licensing fee and related expenses [7][8] - The offering includes common shares and warrants, with potential finders' fees of up to 7% [8][10]

Core Insights - Destiny Media Technologies Inc. announced its financial results for the fiscal year ended August 31, 2025, highlighting a focus on technology modernization and revenue growth [1][2]. Fiscal Year 2025 Highlights - The company completed a multi-year technology modernization effort, essential for scalability and long-term competitiveness [2]. - Revenue growth was reported at 2.3%, with a currency-adjusted growth of 2.6% [9]. - The net loss for the year was $0.6 million, primarily due to higher amortization of capitalized development investments [9]. Technology Modernization Milestones - The migration of the largest enterprise customer to the new platform was completed, significantly reducing technical debt and support requirements [3]. - The launch of MTR™ in late 2024 targeted the radio airplay tracking market, establishing early adoption and customer foundation [4]. - The legacy list management module was fully rebuilt and replaced in April 2025, consolidating revenue-generating workflows onto the modern platform [6]. Product Enhancements - The introduction of self-service and checkout capabilities in 2025 aimed to streamline customer adoption and reduce onboarding friction [8]. - The combination of MTR™ and Play MPE® platforms offers unique cross-marketing opportunities and data-driven insights, enhancing the value proposition [5]. Financial Performance - Service revenue for fiscal 2025 was $4.52 million, compared to $4.42 million in fiscal 2024 [16]. - Gross margin decreased to 84.8% from 86.2% in the previous year [17]. - Operating expenses increased to $4.50 million from $3.75 million in fiscal 2024, with significant increases in product development and depreciation [17]. Balance Sheet Overview - Total assets decreased to $2.97 million from $3.69 million in the previous year [18]. - Cash and cash equivalents were reported at $1.12 million, down from $1.48 million [18]. - Stockholders' equity decreased to $2.42 million from $3.17 million, reflecting an accumulated deficit of $5.83 million [19].

Core Insights - Thiogenesis Therapeutics plans to initiate a Phase 3 pivotal clinical trial for TTI-0102, targeting nephropathic cystinosis, with an Investigational New Drug (IND) application expected in early 2026 [1][10] Group 1: Company Overview - Thiogenesis Therapeutics is a clinical-stage biotechnology company focused on developing sulfur-based prodrugs for rare mitochondrial and metabolic diseases [10] - The company is publicly traded on the TSX Venture Exchange and OTCQX, with operations based in San Diego, California [10] Group 2: Product Details - TTI-0102 is a next-generation cysteamine-based prodrug designed to improve tolerability and simplify dosing compared to existing therapies [3][4] - The drug consists of two cysteamine molecules and one molecule of pantothenic acid (Vitamin B5), allowing for once-daily dosing with reduced peak-related toxicity [9] Group 3: Clinical Trial Insights - The Phase 3 trial will utilize established endpoints and trial design informed by biomarker and tolerability data from the ongoing MELAS clinical study [5][7] - The trial aims to address limitations of current cysteamine therapies, which require multiple daily doses and are associated with significant side effects [2][13] Group 4: Market Opportunity - The global population of cystinosis patients exceeds 2,000, representing a market opportunity of over $300 million [2]